NasdaqGS - Delayed Quote USD

Innoviva, Inc. (INVA)

15.16 -0.01 (-0.07%)
At close: April 24 at 4:00 PM EDT
15.16 0.00 (0.00%)
After hours: April 24 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
310,463.00
310,463.00
331,339.00
391,866.00
336,794.00
Cost of Revenue
42,640.00
42,640.00
13,793.00
--
--
Gross Profit
267,823.00
267,823.00
317,546.00
391,866.00
336,794.00
Operating Expense
153,938.00
153,938.00
110,551.00
16,763.00
15,671.00
Operating Income
113,885.00
113,885.00
206,995.00
375,103.00
321,123.00
Net Non Operating Interest Income Expense
-3,339.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
Other Income Expense
83,552.00
83,552.00
89,374.00
87,404.00
49,929.00
Pretax Income
194,098.00
194,098.00
286,949.00
445,276.00
354,245.00
Tax Provision
14,376.00
14,376.00
66,687.00
76,439.00
60,431.00
Net Income Common Stockholders
179,722.00
179,722.00
213,921.00
265,854.00
224,402.00
Average Dilution Earnings
11,582.00
11,582.00
11,648.00
4,736.00
4,717.00
Diluted NI Available to Com Stockholders
191,304.00
191,304.00
225,569.00
270,590.00
229,119.00
Basic EPS
2.75
2.75
3.07
3.24
2.21
Diluted EPS
2.20
2.20
2.37
2.87
2.02
Basic Average Shares
65,435.00
65,435.00
69,644.00
82,062.00
101,320.00
Diluted Average Shares
86,876.00
86,876.00
95,248.00
94,310.00
113,554.00
Total Operating Income as Reported
--
--
-36,946.00
375,103.00
321,123.00
Total Expenses
196,578.00
196,578.00
124,344.00
16,763.00
15,671.00
Net Income from Continuing & Discontinued Operation
179,722.00
179,722.00
213,921.00
265,854.00
224,402.00
Normalized Income
169,417.28
169,417.28
18,569.92
260,355.52
223,766.67
Interest Income
15,818.00
15,818.00
6,369.00
1,839.00
1,524.00
Interest Expense
19,157.00
19,157.00
15,789.00
19,070.00
18,331.00
Net Interest Income
-3,339.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
EBIT
213,255.00
213,255.00
302,738.00
464,346.00
372,576.00
EBITDA
235,039.00
235,039.00
308,319.00
464,346.00
386,416.00
Reconciled Cost of Revenue
42,640.00
42,640.00
13,793.00
--
--
Reconciled Depreciation
21,784.00
21,784.00
5,581.00
--
13,840.00
Net Income from Continuing Operation Net Minority Interest
179,722.00
179,722.00
213,921.00
265,854.00
224,402.00
Total Unusual Items Excluding Goodwill
11,129.00
11,129.00
254,496.00
6,638.00
766.00
Total Unusual Items
11,129.00
11,129.00
254,496.00
6,638.00
766.00
Normalized EBITDA
223,910.00
223,910.00
53,823.00
457,708.00
385,650.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
824.28
824.28
59,144.92
1,139.52
130.67
12/31/2020 - 10/5/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TYRA Tyra Biosciences, Inc.
16.00
-2.32%
 
IMCR Immunocore Holdings plc
58.47
+2.02%
 
DYN Dyne Therapeutics, Inc.
24.98
-1.81%
 
PTCT PTC Therapeutics, Inc.
25.21
-0.79%
 
ITOS iTeos Therapeutics, Inc.
10.57
-3.82%
 
TRDA Entrada Therapeutics, Inc.
12.43
-3.57%
 
PHVS Pharvaris N.V.
21.25
-0.19%
 
PTGX Protagonist Therapeutics, Inc.
25.70
-4.28%
 
REPL Replimune Group, Inc.
6.33
-1.40%
 
MLTX MoonLake Immunotherapeutics
42.43
-1.90%